Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000597515 | SCV000704048 | uncertain significance | not provided | 2018-05-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001087648 | SCV001035361 | likely benign | Peroxisome biogenesis disorder | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Elsea Laboratory, |
RCV001250061 | SCV001424264 | uncertain significance | Peroxisome biogenesis disorder 8A (Zellweger); Peroxisome biogenesis disorder 8B | 2020-04-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000597515 | SCV003814848 | uncertain significance | not provided | 2019-05-16 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003945398 | SCV004760022 | likely benign | PEX16-related disorder | 2022-12-07 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |